Locoregionally advanced XXXX treated with intensity-modulated radiotherapy plus concurrent weekly @entity900 with or without neoadjuvant chemotherapy.

@entity1 @entity5 @entity900 @entity33 @entity189 @entity1503 @entity3
PURPOSE: The outcomes of locoregionally advanced @entity189 @entity1 treated with concurrent chemoradiation (CCRT) using intensity-modulated radiotherapy (IMRT) with/without neoadjuvant chemotherapy (NCT) were evaluated. MATERIALS AND METHODS: Eighty-three @entity1 who underwent NCT followed by CCRT (49%) or CCRT with/without adjuvant chemotherapy (51%) were reviewed. To the gross @entity5 , 67.5 Gy was prescribed. Weekly @entity900 was used as concurrent chemotherapy. RESULTS: With a median follow-up of 49.4 months, the 5-year local control, regional control, distant @entity3 -free survival (DMFS), disease-free survival (DFS), and overall survival rates were 94.7%, 89.3%, 77.8%, 68.0%, and 81.8%, respectively. In multivariate analysis, the American Joint Committee on @entity5 stage (p = 0.016) and N stage (p = 0.001) were negative factors for DMFS and DFS, respectively. Overall, NCT demonstrated no benefit and an increased risk of severe @entity1503 . However, compared to @entity1 treated with CCRT alone, NCT showed potential of improving DMFS in stage IV @entity1 . CONCLUSION: CCRT using IMRT resulted in excellent local control and survival outcome. Without evidence of survival benefit from phase III randomized trials, NCT should be carefully administered in locoregionally advanced @entity189 @entity1 who are at high-risk of developing distant @entity3 and radiotherapy-related @entity33 . The results of ongoing trials are awaited.
